Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Winer, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Winer, E. P.
Journal of Clinical Oncology, Vol 18, Issue 6 (March), 2000: 1212-1219
© 2000 American Society for Clinical Oncology

Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer

By Harold J. Burstein, Judith Manola, Jerry Younger, Leroy M. Parker, Craig A. Bunnell, Rochelle Scheib, Ursula A. Matulonis, Judy E. Garber, Kathryn D. Clarke, Lawrence N. Shulman, Eric P. Winer

From the Breast Oncology Center; Departments of Adult Oncology and Biostatistical Science, Dana-Farber Cancer Institute; Department of Medicine, Brigham & Women’s Hospital; Division of Hematology/Oncology, Massachusetts General Hospital; and Harvard Medical School, Boston, MA.

Address reprint requests to Eric P. Winer, MD, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; email ewiner{at}partners.org

PURPOSE: To evaluate the safety and efficacy of weekly docetaxel in women with metastatic breast cancer.

PATIENTS AND METHODS: Twenty-nine women were enrolled onto a study of weekly docetaxel given at 40 mg/m2/wk. Each cycle consisted of 6 weeks of therapy followed by a 2-week treatment break, repeated until disease progression or removal from study for toxicity or patient preference. Fifty-two percent of patients had been previously treated with adjuvant chemotherapy; 21% had received prior chemotherapy for metastatic breast cancer, and 31% had previously received anthracyclines. All patients were assessable for toxicity; two patients were not assessable for response but are included in an intent-to-treat analysis.

RESULTS: Patients received a median of 18 infusions, with a median cumulative docetaxel dose of 720 mg/m2. There were no complete responses. Twelve patients had partial responses (overall response rate, 41%; 95% confidence interval, 24% to 61%), all occurring within the first two cycles. Similar response rates were observed among subgroups of patients previously treated either with any prior chemotherapy or with anthracyclines. An additional 17% of patients had stable disease for at least 6 months. The regimen was generally well tolerated. There was no grade 4 toxicity. Only 28% of patients had any grade 3 toxicity, most commonly neutropenia and fatigue. Acute toxicity, including myelosuppression, was mild. Fatigue, fluid retention, and eye tearing/conjunctivitis became more common with repetitive dosing, although these side effects rarely exceeded grade 2. Dose reductions were made for eight of 29 patients, most often because of fatigue (n = 5).

CONCLUSION: Weekly docetaxel is active in treating patients with metastatic breast cancer, with a side effect profile that differs from every-3-weeks therapy.




This article has been cited by other articles:


Home page
 Ann OncolHome page
T. Vu, S. Ellard, C. H. Speers, S. C. M. Taylor, M. L. de Lemos, F. Hu, K. Kuik, and I. A. Olivotto
Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation
Ann. Onc., March 1, 2008; 19(3): 461 - 464.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. D. Colevas
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2644 - 2652.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Ramaswamy, A. D. Elias, N. T. Kelbick, A. Dodley, M. Morrow, M. Hauger, J. Allen, C. Rhoades, K. Kendra, H. X. Chen, et al.
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients.
Clin. Cancer Res., May 15, 2006; 12(10): 3124 - 3129.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Monk, G. Phillips, R. Waite, J. Kuhn, L. J. Schaaf, G. A. Otterson, D. Guttridge, C. Rhoades, M. Shah, T. Criswell, et al.
Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients
J. Clin. Oncol., April 20, 2006; 24(12): 1852 - 1859.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. A. Messersmith, S. D. Baker, L. Lassiter, R. A. Sullivan, K. Dinh, V. I. Almuete, J. J. Wright, R. C. Donehower, M. A. Carducci, and D. K. Armstrong
Phase I Trial of Bortezomib in Combination with Docetaxel in Patients with Advanced Solid Tumors
Clin. Cancer Res., February 15, 2006; 12(4): 1270 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
O. Pagani, C. Sessa, F. Nole, E. Munzone, D. Crivellari, D. Lombardi, B. Thurlimann, D. Hess, R. Graffeo, M. Ruggeri, et al.
Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
Ann. Onc., October 1, 2005; 16(10): 1609 - 1617.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Eniu, F. M. Palmieri, and E. A. Perez
Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer
Oncologist, October 1, 2005; 10(9): 665 - 685.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. Gu, L. Espana, O. Mendez, A. Torregrosa, and A. Sierra
Organ-selective chemoresistance in metastasis from human breast cancer cells: inhibition of apoptosis, genetic variability and microenvironment at the metastatic focus
Carcinogenesis, December 1, 2004; 25(12): 2293 - 2301.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Tabernero, M. A. Climent, A. Lluch, J. Albanell, J. B. Vermorken, A. Barnadas, A. Anton, C. Laurent, J. I. Mayordomo, N. Estaun, et al.
A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer
Ann. Onc., September 1, 2004; 15(9): 1358 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. T. Dang, G. M. D'Andrea, M. E. Moynahan, M. N. Dickler, A. D. Seidman, M. Fornier, M. E. Robson, M. Theodoulou, D. Lake, V. E. Currie, et al.
Phase II Study of Feasibility of Dose-Dense FEC Followed by Alternating Weekly Taxanes in High-Risk, Four or More Node-Positive Breast Cancer
Clin. Cancer Res., September 1, 2004; 10(17): 5754 - 5761.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. D. Hainsworth
Practical Aspects of Weekly Docetaxel Administration Schedules
Oncologist, September 1, 2004; 9(5): 538 - 545.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Marshall, H. Chen, D. Yang, M. Figueira, K. B. Bouker, Y. Ling, M. Lippman, S. R. Frankel, and D. F. Hayes
A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors
Ann. Onc., August 1, 2004; 15(8): 1274 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Gligorov and J. P. Lotz
Preclinical Pharmacology of the Taxanes: Implications of the Differences
Oncologist, June 2, 2004; 9(suppl_2): 3 - 8.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Crown, M. O'Leary, and W.-S. Ooi
Docetaxel and Paclitaxel in the Treatment of Breast Cancer: A Review of Clinical Experience
Oncologist, June 2, 2004; 9(suppl_2): 24 - 32.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K.L. Tedesco, A.D. Thor, D.H. Johnson, Y. Shyr, K.A. Blum, L.J. Goldstein, W.J. Gradishar, B.P. Nicholson, D.E. Merkel, D. Murrey, et al.
Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial
J. Clin. Oncol., March 15, 2004; 22(6): 1071 - 1077.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Baker, M. Zhao, C. K. K. Lee, J. Verweij, Y. Zabelina, J. R. Brahmer, A. C. Wolff, A. Sparreboom, and M. A. Carducci
Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel
Clin. Cancer Res., March 15, 2004; 10(6): 1976 - 1983.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. M. Minisini, A. Tosti, A. F. Sobrero, M. Mansutti, B. M. Piraccini, C. Sacco, and F. Puglisi
Taxane-induced nail changes: incidence, clinical presentation and outcome
Ann. Onc., February 1, 2003; 14(2): 333 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes
Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study
Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens
Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview
Oncologist, December 1, 2002; 7(6): 516 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Monnerat, S. Faivre, S. Temam, J. Bourhis, and E. Raymond
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
Ann. Onc., July 1, 2002; 13(7): 995 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. V. Kornek, K. Haider, W. Kwasny, M. Raderer, B. Schull, T. Payrits, D. Depisch, E. Kovats, F. Lang, and W. Scheithauer
Treatment of Advanced Breast Cancer with Docetaxel and Gemcitabine with and without Human Granulocyte Colony-stimulating Factor
Clin. Cancer Res., May 1, 2002; 8(5): 1051 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Fritsche, et al.
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer
J. Clin. Oncol., April 1, 2002; 20(7): 1800 - 1808.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Esmaeli, G. Hortobagyi, F. Esteva, V. Valero, M. A. Ahmadi, D. Booser, N. Ibrahim, E. Delpassand, and R. Arbuckle
Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect
Ann. Onc., February 20, 2002; 13(2): 218 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Aihara, Y. Kim, and Y. Takatsuka
Phase II study of weekly docetaxel in patients with metastatic breast cancer
Ann. Onc., February 20, 2002; 13(2): 286 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. S. Kerbel, G. Klement, K. I. Pritchard, and B. Kamen
Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic
Ann. Onc., January 19, 2002; 13(1): 12 - 15.
[Full Text] [PDF]

Home page
 Arch OphthalmolHome page
M. A. Ahmadi and B. Esmaeli
Surgical Treatment of Canalicular Stenosis in Patients Receiving Docetaxel Weekly
Arch Ophthalmol, December 1, 2001; 119(12): 1802 - 1804.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Esmaeli and G. N. Hortobagyi
Canalicular Stenosis as the Underlying Mechanism for Epiphora in Patients Receiving Weekly Docetaxel
Oncologist, December 1, 2001; 6(6): 551 - 552.
[Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, H. A. Burris III, D. A. Yardley, J. E. Bradof, M. Grimaldi, L. A. Kalman, T. Sullivan, M. Baker, J. B. Erland, and F. A. Greco
Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial
J. Clin. Oncol., August 1, 2001; 19(15): 3500 - 3505.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Baselga and J. M. Tabernero
Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy
Oncologist, June 1, 2001; 6(2008): 26 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Hata, J. Kitayama, M. Shinozaki, Y. Komuro, T. Watanabe, T. Takano, S. Iwase, and H. Nagawa
Intestinal Perforation Due to Metastasis of Breast Carcinoma, with Special Reference to Chemotherapy: a Case Report
Jpn. J. Clin. Oncol., April 1, 2001; 31(4): 162 - 164.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Oncologist, April 1, 2001; 6(2): 133 - 146.
[Abstract] [Full Text]

Home page
 JCOHome page
G. V. Kornek, H. Ulrich-Pur, M. Penz, K. Haider;, W. Kwasny, D. Depisch, E. Kovats, F. Lang, B. Schneeweiss, and W. Scheithauer
Treatment of Advanced Breast Cancer with Vinorelbine and Docetaxel With or Without Human Granulocyte Colony-Stimulating Factor
J. Clin. Oncol., February 1, 2001; 19(3): 621 - 627.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online